ArticleScientific reports2025
SMENN-hybrid: an efficient technique combining the synthetic minority oversampling technique with ensemble learning for diabetes prediction.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- An LLM-based synthetic data generation approach for addressing class imbalance in malicious traffic detection.Scientific reports · 2026Article
- Explainable Meta-Learning Ensemble Framework for Predicting Insulin Dose Adjustments in Diabetic Patients: A Comparative Machine Learning Approach with SHAP-Based Clinical Interpretability.Medicina (Kaunas, Lithuania) · 2026Article
- An explainable machine learning approach to predicting carbapenem resistance inFrontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Diabetes Mellitus (DM) is a chronic metabolic disorder and a major global health problem, with many cases undiagnosed. Early detection and effective management are essential to prevent complications. This paper presents an efficient hybrid technique that combine the Synthetic Minority Oversampling Technique combined with Edited Nearest Neighbors (SMOTE-ENN) with ensemble learning termed (SMENN-Hybrid). Gradient Boosting was identified as the most effective ensemble method through rigorous multi-metric evaluation. The proposed approach was rigorously evaluated across five diverse datasets: PIMA India, Diabetes Prediction Dataset (DPD), Diabetes Dataset 2019, Raw Merged Dataset (RMD), and Cleaned Merged Dataset (CMD). A comprehensive multi-metric assessment considering F1-Score, ROC-AUC, and Accuracy demonstrated exceptional generalizability, with Gradient Boosting achieving a composite score of 99.93/100 and maintaining coefficients of variation below 2% across all metrics (mean F1=0.9860, ROC-AUC=0.9990, Accuracy=0.9860). 5-fold stratified cross-validation confirmed remarkable stability (overall CV < 1.65% for all metrics), while systematic ablation studies validated the essential synergy between SMOTE and ENN, showing average improvements of +16.78% in F1-Score and +29.47% in Recall over unbalanced baselines. Compared to traditional methods (Logistic Regression and Decision Tree), the proposed framework achieved consistent improvements of +2.99% average F1-Score over the best baseline, with individual dataset gains ranging from +3.25% to +3.99%. Despite 246× longer training time, inference remains practical at 2.47ms, making the approach suitable for real-time clinical deployment. The combination of high effectiveness (mean F1=0.9841), exceptional consistency (CV < 2%), and comprehensive validation across multiple datasets and evaluation dimensions positions this framework as a clinically deployable solution for diabetes detection without dataset-specific tuning, offering significant advantages for similar healthcare classification tasks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.